PAX1

Across TCGA pan-cancer cohorts, PAX1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PAX1 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher PAX1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAX1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PCPG, LIHC, and SCLC are the cancer types where PAX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.190	0.967	<.001	15	view →
LIHC	OS	Median	All	0.433	0.785	.004	9	view →
SCLC	DFS	Median	III,IV	0.178	0.557	.024	6	view →
ESCA	OS	Median	II,III,IV	0.297	0.695	.005	6	view →
HNSC	DFS	Median	II,III,IV	1.000	0.339	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PAX1–PCPG (OS)

Open the PCPG breakdown →